The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Tafamidis for the treatment of TTR cardiac amyloidosis
Giampaolo Merlini
• 14 Sep 2019
Giampaolo Merlini, MD University of Pavia, Pavia, Italy, provides an overview of the use of tafamidis in the treatment of transthyretin cardiac amyloidosis at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
